Tags

Type your tag names separated by a space and hit enter

Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society.
JAMA 2015; 314(15):1599-614JAMA

Abstract

IMPORTANCE

Breast cancer is a leading cause of premature mortality among US women. Early detection has been shown to be associated with reduced breast cancer morbidity and mortality.

OBJECTIVE

To update the American Cancer Society (ACS) 2003 breast cancer screening guideline for women at average risk for breast cancer.

PROCESS

The ACS commissioned a systematic evidence review of the breast cancer screening literature to inform the update and a supplemental analysis of mammography registry data to address questions related to the screening interval. Formulation of recommendations was based on the quality of the evidence and judgment (incorporating values and preferences) about the balance of benefits and harms.

EVIDENCE SYNTHESIS

Screening mammography in women aged 40 to 69 years is associated with a reduction in breast cancer deaths across a range of study designs, and inferential evidence supports breast cancer screening for women 70 years and older who are in good health. Estimates of the cumulative lifetime risk of false-positive examination results are greater if screening begins at younger ages because of the greater number of mammograms, as well as the higher recall rate in younger women. The quality of the evidence for overdiagnosis is not sufficient to estimate a lifetime risk with confidence. Analysis examining the screening interval demonstrates more favorable tumor characteristics when premenopausal women are screened annually vs biennially. Evidence does not support routine clinical breast examination as a screening method for women at average risk.

RECOMMENDATIONS

The ACS recommends that women with an average risk of breast cancer should undergo regular screening mammography starting at age 45 years (strong recommendation). Women aged 45 to 54 years should be screened annually (qualified recommendation). Women 55 years and older should transition to biennial screening or have the opportunity to continue screening annually (qualified recommendation). Women should have the opportunity to begin annual screening between the ages of 40 and 44 years (qualified recommendation). Women should continue screening mammography as long as their overall health is good and they have a life expectancy of 10 years or longer (qualified recommendation). The ACS does not recommend clinical breast examination for breast cancer screening among average-risk women at any age (qualified recommendation).

CONCLUSIONS AND RELEVANCE

These updated ACS guidelines provide evidence-based recommendations for breast cancer screening for women at average risk of breast cancer. These recommendations should be considered by physicians and women in discussions about breast cancer screening.

Authors+Show Affiliations

Memorial Sloan Kettering Cancer Center, New York, New York.Louisiana State University School of Public Health, New Orleans.University of Washington and the Fred Hutchinson Cancer Research Center, Seattle.Patient advocate, Troy, New York.Massachusetts General Hospital and Harvard Medical School, Boston.University of Texas MD Anderson Cancer Center, Houston.University of California, San Francisco, and San Francisco VA Medical Center.Masonic Cancer Center and the University of Minnesota, Minneapolis.Emory University School of Medicine and Winship Cancer Institute, Atlanta, Georgia.Independent retired physician and patient advocate.University of Virginia School of Medicine, Charlottesville.American Cancer Society, Atlanta, Georgia.American Cancer Society, Atlanta, Georgia.American Cancer Society, Atlanta, Georgia.American Cancer Society, Atlanta, Georgia.American Cancer Society, Atlanta, Georgia.American Cancer Society, Atlanta, Georgia.American Cancer Society, Atlanta, Georgia.American Cancer Society, Atlanta, Georgia.No affiliation info available

Pub Type(s)

Journal Article
Practice Guideline
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26501536

Citation

Oeffinger, Kevin C., et al. "Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society." JAMA, vol. 314, no. 15, 2015, pp. 1599-614.
Oeffinger KC, Fontham ET, Etzioni R, et al. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. JAMA. 2015;314(15):1599-614.
Oeffinger, K. C., Fontham, E. T., Etzioni, R., Herzig, A., Michaelson, J. S., Shih, Y. C., ... Wender, R. (2015). Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. JAMA, 314(15), pp. 1599-614. doi:10.1001/jama.2015.12783.
Oeffinger KC, et al. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. JAMA. 2015 Oct 20;314(15):1599-614. PubMed PMID: 26501536.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. AU - Oeffinger,Kevin C, AU - Fontham,Elizabeth T H, AU - Etzioni,Ruth, AU - Herzig,Abbe, AU - Michaelson,James S, AU - Shih,Ya-Chen Tina, AU - Walter,Louise C, AU - Church,Timothy R, AU - Flowers,Christopher R, AU - LaMonte,Samuel J, AU - Wolf,Andrew M D, AU - DeSantis,Carol, AU - Lortet-Tieulent,Joannie, AU - Andrews,Kimberly, AU - Manassaram-Baptiste,Deana, AU - Saslow,Debbie, AU - Smith,Robert A, AU - Brawley,Otis W, AU - Wender,Richard, AU - ,, PY - 2015/10/27/entrez PY - 2015/10/27/pubmed PY - 2015/11/5/medline SP - 1599 EP - 614 JF - JAMA JO - JAMA VL - 314 IS - 15 N2 - IMPORTANCE: Breast cancer is a leading cause of premature mortality among US women. Early detection has been shown to be associated with reduced breast cancer morbidity and mortality. OBJECTIVE: To update the American Cancer Society (ACS) 2003 breast cancer screening guideline for women at average risk for breast cancer. PROCESS: The ACS commissioned a systematic evidence review of the breast cancer screening literature to inform the update and a supplemental analysis of mammography registry data to address questions related to the screening interval. Formulation of recommendations was based on the quality of the evidence and judgment (incorporating values and preferences) about the balance of benefits and harms. EVIDENCE SYNTHESIS: Screening mammography in women aged 40 to 69 years is associated with a reduction in breast cancer deaths across a range of study designs, and inferential evidence supports breast cancer screening for women 70 years and older who are in good health. Estimates of the cumulative lifetime risk of false-positive examination results are greater if screening begins at younger ages because of the greater number of mammograms, as well as the higher recall rate in younger women. The quality of the evidence for overdiagnosis is not sufficient to estimate a lifetime risk with confidence. Analysis examining the screening interval demonstrates more favorable tumor characteristics when premenopausal women are screened annually vs biennially. Evidence does not support routine clinical breast examination as a screening method for women at average risk. RECOMMENDATIONS: The ACS recommends that women with an average risk of breast cancer should undergo regular screening mammography starting at age 45 years (strong recommendation). Women aged 45 to 54 years should be screened annually (qualified recommendation). Women 55 years and older should transition to biennial screening or have the opportunity to continue screening annually (qualified recommendation). Women should have the opportunity to begin annual screening between the ages of 40 and 44 years (qualified recommendation). Women should continue screening mammography as long as their overall health is good and they have a life expectancy of 10 years or longer (qualified recommendation). The ACS does not recommend clinical breast examination for breast cancer screening among average-risk women at any age (qualified recommendation). CONCLUSIONS AND RELEVANCE: These updated ACS guidelines provide evidence-based recommendations for breast cancer screening for women at average risk of breast cancer. These recommendations should be considered by physicians and women in discussions about breast cancer screening. SN - 1538-3598 UR - https://www.unboundmedicine.com/medline/citation/26501536/full_citation L2 - https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2015.12783 DB - PRIME DP - Unbound Medicine ER -